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phrenia who were treated with antipsychotic medications
during their first post-treatment year. Data were drawn
from January 1987 to July 1996. Allowances were made
for titration and changes in therapy. Multiple logistic re-
gression models were used to identify factors affecting ti-
tration success and conformance. OLS regression models
were used to estimate the impact of the PORT conform-
ance on health care costs. RESULTS: Only 16.9% of the
2,567 patients treated with antipsychotic drugs achieved
conformance with PORT recommendations. Fewer than
50% patients achieved titration success on their initial
drugs, and the likelihood of PORT conformance in-
creased with initial dose. Patients who received at least
the minimum therapeutic dose on their first prescription
were 2.9 times more likely to achieve conformance than
patients who were prescribed less than 50% of the mini-
mum dose (P  0.0001). This odds ratio increased to 8.2
for patients treated initially at 3 times minimum dose
(P  0.0001). Patients treated initially with fluphenazine
were more likely to achieve conformance (odds ratio 
1.834, P  .0001), while thioridazine patients were less
likely to conform (0.436, P  0.0228). PORT conform-
ance was not associated with lower total costs ($2,543,
P  0.2453). CONCLUSION: In clinical practice, the
rate PORT conformance was low and conformance did
not significantly reduce total direct health care costs.
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Previous investigations examining healthcare resource
utilization in patient populations have shown mi-
graineurs to consume significantly higher healthcare re-
sources versus non-migraineurs. However, there is a
dearth of healthcare resource utilization data within mi-
graine populations that examine a specific pharmaceuti-
cal’s impact on resource utilization. OBJECTIVE: To
compare healthcare resource and narcotic use in mi-
graineurs prescribed sumatriptan (oral, subcutaneous, or
nasal) versus migraineurs not prescribed sumatriptan.
DESIGN: A review of the 1998 Idaho Medicaid claims
database was performed. METHODS: Migraine patients
greater than four years of age were identified using two
inclusion criteria—physician diagnosed cases identified
by specific ICD-9-CM codes or patients prescribed mi-
graine-specific drugs. Comorbidity was identified using
specific diagnostic categories. Total healthcare resource
utilization, reported in dollars, was the sum amount paid
by Idaho Medicaid for all medications including anti-mi-
graine prescriptions, physician services, hospital services
(outpatient and inpatient), and emergency room services.
Logarithmic transformations were performed on depen-
dent variables. Linear regression modeling was per-
formed to determine predictors of resource utilization.
RESULTS: 498 migraineurs were identified. Patient char-
acteristics, including presence/absence of comorbidity,
showed no differences between the two groups. Mi-
graineurs prescribed sumatriptan had significantly lower
hospital visits (P  0.01), physician visits (P  0.01),
physician service fees (P  0.05), and fees paid for nar-
cotics (P  0.05). Sumatriptan prescription was not a sig-
nificant predictor of total healthcare utilization (P 
0.05), nor of narcotic use (P  0.05). CONCLUSIONS:
While migraine patients have higher healthcare resource
utilization, this study indicated that sumatriptan users
had significantly lower healthcare resource utilization
than non-sumatriptan users. However, we found that
sumatriptan use was not a significant predictor of higher
healthcare resource dollars.
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Results from a recent trial suggest that combination of
nefazodone and Cognitive Behavioral Analysis System of
Psychotherapy (CBASP) is more efficacious than either
modality alone in the treatment of chronic depression.
OBJECTIVES: This analysis examines the relationship
between treatment modality, clinical measures of depres-
sion severity, measures of patient functioning, and eco-
nomic outcomes. METHODS: Outcomes data from the
12-week acute phase of a 12-site trial investigating the
therapeutic efficacy of nefazodone, CBASP and their
combination using symptom and functional metrics are
combined with medical claims data encompassing 1.4
million lives (MarketScan, The MEDSTAT Group) used
to attribute costs to clinical interventions. Economic ben-
efits of treatment are calculated by multiplying patient in-
come and proportional changes in functional capacity.
Modified versions of the Social Adjustment Scale (SAS),
SF-36, and L.I.F.E. are used to determine functional ca-
pacity. RESULTS: Work impairment improved signifi-
cantly for all groups, but is greatest for combination ther-
apy (P  0.02). This pattern is also observed for the
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overall SAS score (P  0.001). Baseline to week 4 differ-
ences in overall SAS demonstrate significantly greater im-
provement for nefazodone mono-therapy compared to
CBASP mono-therapy (P  0.032). Conservative esti-
mates of mean direct treatment costs per patient irrespec-
tive of response are $770 (nefazodone), $1800 (CBASP)
and $2500 (combination). Estimated mean direct treat-
ment costs per acute responder are $1700 (nefazodone),
$4000 (CBASP), and $3400 (combination). Multivariate
results are presented that highlight the interrelationships
of treatment modality, disease severity (HAM-D), func-
tional status (SAS, SF-36, and L.I.F.E.) and costs of treat-
ment. CONCLUSIONS: Combination treatment is most
efficacious. Direct treatment cost per acute responder is
lowest for treatments using nefazodone. Further cost-effec-
tiveness results incorporating variation in time-to-response,
other direct costs, and economic benefits associated with
treatment will also be presented.
PMH39
HEALTH CARE BURDEN AND COST OF 
PARKINSON’S DISEASE
Wilson L1, Huang J2, Doshi D3
1Pharmaceutical Policy and Economics, University of California, 
San Francisco, CA, USA; 2School of Pharmacy, University of 
California, San Francisco, CA, USA; 3SmithKline Beecham, 
Philadelphia, PA, USA
OBJECTIVES: Parkinson’s disease is a progressive neu-
rodegenerative disease and important contributor to dis-
ability. We demonstrated health care status, utilization of
health services and total direct costs of Parkinson’s dis-
ease. METHODS: We used a prevalence approach and
aggregate national data sources to determine 1997 US
annual direct medical cost and general health status of
Parkinson’s patients from a societal perspective. A sensi-
tivity analysis varied prevalence and utilization of each
cost factor around a base case. RESULTS: The preva-
lence of idiopathic Parkinson’s disease is 283/100,000
population, of which 82% are greater than 65 years.
Only 3% of the population with Parkinson’s disease re-
port that they are in excellent health, 11% very good,
19% good, 29% fair and 38% in poor health. Total di-
rect costs are $6.6 billion, $3.4 billion for men. Nursing
home costs ($2.9 billion) account for the largest propor-
tion (44%) of these costs, with medications second
($1.95 billion, 29%) and hospitalizations third most
costly ($1.1 billion, 17%). This is about $8,738 per per-
son annually. The elderly carry the greatest cost burden,
highest for the 75–84 year olds ($2.6 billion annually).
Sensitivity analysis showed a maximum variation in cost
from $3.3 to $9.4 billion when varying both utilization
and prevalence estimates. CONCLUSIONS: The societal
cost burden is high considering the low prevalence of the
disease. Other chronic diseases generally cost only $1–
2,000 annually per patient. There is a large self-perceived
health burden, with the majority of patients reporting
“poor” health status. This study demonstrates a high
combined economic and social burden for Parkinson’s
disease patients.
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OBJECTIVE: To assess factors that influence whether
patients with schizophrenia are prescribed second-gener-
ation antipsychotic medications (olanzapine, risperidone)
or traditional antipsychotics. METHODS: Data were ob-
tained from the Schizophrenia Care and Assessment Pro-
gram study. Participant information was collected through
interviews and medical record abstraction (n  294).
Treating physicians were surveyed about their demo-
graphic, professional, and practice characteristics (n 
42). Patient and physician information was linked. Mul-
tivariate logistic regression with patient and physician-
level predictors was estimated. RESULTS: The following
variables were positively associated with second-genera-
tion medication use at P  0.05: a higher baseline
PANSSNS score (e.g. depressed affect), having a physi-
cian who has been in practice less than five years or
greater than 20 years, one who has attended more than
one professional meeting in the last five years, and one
who sees more than 25 patients a week. The following
variables were positively associated with second-genera-
tion medication use at P  0.1 in some of the models: pa-
tient age 35, race other than African-American or White,
diagnosis of other schizophrenia, being uninsured, and
having one or no prior psychotic episodes. Medicare, Med-
icaid, private insurance, CHAMPUS, and other insurance
were not significant predictors. CONCLUSIONS: One of
the perceived advantages of second-generation antipsy-
chotic medications over traditional antipsychotics is their
greater effectiveness at reducing the negative symptoms
of schizophrenia. Consistent with this belief, we find that
physicians are prescribing second-generation antipsy-
chotics to patients who display more negative symptoms.
There is also evidence that physicians may be prescribing
second-generation antipsychotics to younger patients and
those experiencing a first psychotic episode, thus using
second-generation medications as first-line treatments.
We also find that physician characteristics are influencing
whether patients are being prescribed the second-genera-
tion medications. Finally, we do not find evidence that
insurance status influences access to medications.
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